HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients - 06/10/17

Doi : 10.1016/j.jinf.2017.05.011

M.A. Colombier ^a, S. Amorim ^b,^c, M. Salmona ^d, C. Thieblemont ^b,^c, J. Legoff ^d, M. Lafaurie ^a,^⁎
^a Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
^b Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
^c Paris Diderot University, Sorbonne Paris Cité, Paris, France
^d Microbiology Laboratory, Inserm U941, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris Diderot University, Paris, France

^∗Corresponding author. Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Fax: +33 (0) 1 42 49 90 67.Service de Maladies Infectieuses et TropicalesHôpital Saint-Louis1 Avenue Claude VellefauxParis75010France

Summary

Objectives

We report the biological and clinical impacts possibly associated with HHV-6 reactivation in autologous hematopoietic stem cell transplant (AHSCT) recipients after intensive chemotherapy regimen for lymphoma.

Methods

We retrospectively reviewed clinical, biological, radiological, treatment and outcomes of patients with positive HHV-6 DNA in whole blood following autologous hematopoietic stem cell transplantation.

Results

Blood HHV-6 reactivation was reported in 27 (8.5%) patients among 316 AHSCT recipients after high dose therapy for lymphoma. Thirteen (4.1%) patients were symptomatic with fever (100%), diarrhea (61.5%), skin rash (46.1%), and pneumonia (23.1%). Antiviral treatment was administered in 9 (69%) patients and outcome was favorable in all cases.

Conclusion

Our study suggests a possible pathogenic role of HHV-6 in AHSCT recipients and suggests an impact of antiviral treatments on viral replication and clinical signs resolution.

Le texte complet de cet article est disponible en PDF.

Highlights

•	HHV-6 was possibly associated with unexplained fever in autologous stem cell transplant lymphoma recipients.
•	Diarrhea and/or skin rash and pneumonia were observed in patients with HHV-6 reactivation.
•	Antiviral treatment was required in 9/13 cases and outcome was favorable in all patients.

Le texte complet de cet article est disponible en PDF.

Keywords : HHV-6 reactivation, Autologous hematopoietic stem cell transplantation, Lymphoma, Fever, Antiviral treatment

Plan

Export

Vol 75 - N° 2

P. 155-159 - août 2017 Retour au numéro

Article précédent

Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: A real-world prospective cohort study
Zhi-Xian Chen, Gui-Fang Gu, Zhao-Lian Bian, Wei-Hua Cai, Yi Shen, Yan-Li Hao, Sheng Zhang, Jian-Guo Shao, Gang Qin

| Article suivant

Multiple introductions and onward transmission of HIV-1 subtype B strains in Shanghai, China
Xiaoshan Li, Kexin Zhu, Yile Xue, Feiran Wei, Rong Gao, Ralf Duerr, Kun Fang, Wei Li, Yue Song, Guoping Du, Wenjuan Yan, Taha Hussein Musa, You Ge, Yu Ji, Ping Zhong, Pingmin Wei

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients - 06/10/17

Summary

Objectives

Methods

Results

Conclusion

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL